Immuno-Oncology (IO) – Thematic Intelligence

Powered by

Access in-depth insight and stay ahead of the market

Accessing the in-depth insight from the ‘Immuno-Oncology Market’ report will allow you to –

  • Obtain immuno-oncology market assessment and forecast across multiple regions
  • Gain insight into promising early-stage approaches.
  • Our indication specific forecast models answer questions such as –
    • What is the target patient pool for cell & gene therapies in each cancer indication?
    • Which patient groups are more likely to receive these therapies?
    • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
    • What is the anticipated breakdown between autologous and allogeneic cell therapies?
    • When will cell & gene therapies launch in each market?
    • What is the total market value projected for the forecast end, in 2028?

How is the ‘Immuno-Oncology Market’ report different from other reports in the market?

  • Acquire in-depth analysis of the rapidly evolving IO landscape with Industry trends for each of the IO classes – including checkpoint modulators, cell therapies, bispecific antibodies, therapeutic vaccines, oncolytic viruses, and cytokines.
  • Gain insights into market leaders and market challengers for each IO class, with an in-depth analysis of leading and emerging brands and companies.
  • Analyze the IO pipeline, with emerging technologies, targets, and biomarkers identified along with IO clinical trial design and endpoints. The report also covers deals within the IO sector, including strategic partnerships, mergers, and acquisitions.
  • Leverage the regulatory framework and reimbursement strategies for IO therapies across markets. Beyond reimbursement hurdles, other barriers to access to IO therapies are also explored.
  • Identification of unmet clinical and commercial needs within the IO field and agents and strategies that may address these.

We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical companies
  • Biotech
  • CMOs and CDMOs
  • Consulting Companies
  • Technology Companies, Start-ups
  • Professional Services (e.g., Investment, Equity Companies, Banks)

To Get a Snapshot of the Immuno-Oncology Market Report, download a free report sample

Immuno Oncology Market Thematic Intelligence Overview

The immuno-oncology (IO) market size was valued at $48 billion in 2022 and is expected to grow at a CAGR of over 21% during 2022-2028. IO refers to the development of therapies that utilize the human body’s immune responses, both adaptive and innate, to target cancer. Most of the mechanisms involved in human immune responses revolve around priming and boosting the immune system via the stimulation of antigen-presenting cells, T-cells, or innate cells, reducing immunosuppression in the tumor environment by regulating inhibitory pathways, and enhancing adaptive or innate immunity. IO therapies differ from passive strategies that include administration of immune system components, which results in temporary anti-tumoral effects.

Immuno-Oncology Market Outlook, 2022-2028 ($ Billion)

Immuno-Oncology Market Outlook, 2022-2028 ($ Billion)

For more insights on the immuno-oncology market forecast, download a free report sample

The immuno-oncology thematic research report gives an overview of key marketed and pipeline immuno-oncology drugs including classification of therapy and technologies, regulatory and market access details, and product & company profiles. It analyses the key dynamics of the IO market and provides the key industry drivers and challenges.

Report Pages 169
Regions Covered Global
Market Size (2022) $48 Billion
CAGR (2022-2028) >21%
Value Chain Bispecific Antibodies, Oncolytic Viruses, Cell Therapies, Cancer Vaccines, Checkpoint Modulators, and Cytokines
Key Types (Marketed Products) Cytokines, Bispecific Antibodies, Cancer Vaccines, Cell Therapies, Immune Checkpoint Inhibitor, and Oncolytic Viruses
Key Indication (Marketed Products) Melanoma, Kidney Cancer, Liver Cancer, Non-Small Cell Lung Cancer (NSCLC), and Colorectal Cancer
Key Types (Pipeline Products) Cell Therapies, Bispecific Antibodies, Cancer Vaccines, Checkpoint Modulators, Cytokines, and Oncolytic Viruses
Key Indication (Pipeline Products) Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Gastric Cancer, Melanoma, and Colorectal Cancer
Leading Players Novartis Merck & Co., Gilead Sciences, Roche, Bristol Myers Squibb, AstraZeneca, IQVIA, and Sanofi

Immuno-Oncology Market - Trends and Opportunities

The bispecific antibody field has generated a lot of excitement in oncology, with additional BiTEs FDA-approved in the last year. Interest in the cancer vaccine field has also been reignited with the first positive data from an mRNA vaccine announced. In addition, the cell therapy field is impacting more indications and has offered curative options for some blood cancers. CAR-Ts have moved into earlier lines of therapy for non-Hodgkin’s lymphoma (NHL).

Bispecific antibodies are in the unique position to offer T-cell redirection in combination with checkpoint modulation, potentially addressing the T-cell exhaustion issue. Bispecific dual-targeting ICIs may prove to be more effective than using a combination of two ICIs. New ways to alter the tumor microenvironment to combat resistance to IO therapy is also one of the opportunities in the immuno-oncology market.

Immuno-Oncology - Value Chain Analysis

The immuno-oncology value chain consists of bispecific antibodies, oncolytic viruses, cell therapies, cancer vaccines, checkpoint modulators, and cytokines.

Bispecific Antibodies: They aim to bring two different cell or protein types into proximity to promote some biological function. Bispecific T-cell engagers are especially relevant to IO. The current leader in the bispecific antibody segment of IO is Amgen, which was the first company to launch an FDA-approved bispecific T-cell engager antibody (Blincyto) in an oncology indication.

Immuno-Oncology Value Chain Analysis

Immuno-Oncology Value Chain Analysis

For more insights on the Immuno-Oncology value chain, download a free report sample

Immuno-Oncology Marketed Products Segmentation by Types

Cytokines, bispecific antibodies, cancer vaccines, cell therapies, immune checkpoint inhibitors, and oncolytic viruses are the key types of marketed immuno-oncology products in the 8MM. There are currently more than 70 marketed IO agents in the 8MM. Cytokine products lead the category in the immuno-oncology market.

Immuno-Oncology Marketed Products Analysis by Types, as of April 2023

Immuno-Oncology Marketed Products Analysis by Types, as of April 2023

For more insights on the types of marketed immuno-oncology products, download a free report sample

Immuno-Oncology Marketed Products Segmentation by Indication

Melanoma, kidney cancer, liver cancer, non-small cell lung cancer (NSCLC), and colorectal cancer are some of the key indications in the immuno-oncology marketed products in the 8MM. The indications with the most marketed IO agents in the 8MM are melanoma, kidney cancer, liver cancer, and NSCLC.

The majority of approved IO agents are available in China with more than 40 products available, followed by the US.

Immuno-Oncology Marketed Products Analysis by Indication, as of April 2023

Immuno-Oncology Marketed Products Analysis by Indication, as of April 2023

For more insights on the marketed immuno-oncology products by indication, download a free report sample

Immuno-Oncology Pipeline Products Segmentation by Types

Cell therapies, bispecific antibodies, cancer vaccines, checkpoint modulators, cytokines, and oncolytic viruses are the key types of immuno-oncology pipeline products. Cell therapies have the maximum number of pipeline products in the IO market.

Immuno-Oncology Pipeline Products Analysis by Types, as of April 2023

Immuno-Oncology Pipeline Products Analysis by Types, as of April 2023

For more insights on the immuno-oncology pipeline products by type, download a free report sample

Immuno-Oncology Pipeline Products Segmentation by Indication

Solid tumor, non-small cell lung cancer (NSCLC), gastric cancer, melanoma, and colorectal cancer are some of the top indications in the immuno-oncology pipeline products market. Solid tumor has the majority number of pipeline products in the IO market.

Immuno-Oncology Pipeline Products Analysis by Indication, as of April 2023

Immuno-Oncology Pipeline Products Analysis by Indication, as of April 2023

For more insights on the immuno-oncology pipeline products by indication, download a free report sample

Immuno-Oncology - Leading Companies

Some of the leading companies making their mark within the immuno-oncology theme are Novartis Merck & Co., Gilead Sciences, Roche, Bristol Myers Squibb, AstraZeneca, IQVIA, and Sanofi among others.

Novartis: Headquartered in Basel, Switzerland, Novartis is a healthcare company that focuses on the discovery, development, manufacture, and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others.

Segments Covered in the Report

Immuno-Oncology Marketed Products Outlook by Types

  • Cytokines
  • Bispecific Antibodies
  • Cancer Vaccines
  • Cell Therapies
  • Immune Checkpoint Inhibitors
  • Oncolytic Viruses

Immuno-Oncology Marketed Products Outlook by Indication

  • Melanoma
  • Kidney Cancer
  • Liver Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Colorectal Cancer

Pipeline Immuno-Oncology Products Outlook by Types

  • Cell Therapies
  • Bispecific Antibodies
  • Cancer Vaccines
  • Checkpoint Modulators
  • Cytokines
  • Oncolytic Viruses

Pipeline Immuno-Oncology Products Outlook by Indication

  • Solid Tumor
  • Non-Small Cell Lung Cancer (NSCLC)
  • Gastric Cancer
  • Melanoma
  • Colorectal Cancer

Key Players

Novartis AG
Merck & Co Inc
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
Bristol-Myers Squibb Co
AstraZeneca Plc
Amgen Inc
Dendron Inc
Daichi Sankyo Co Ltd
Legend Biotech Corp
Johnson and Johnson
Kite Pharma Inc
Regeneron Pharmaceuticals Inc
Iovance Biotherapeutics Inc
Replimune Inc
VBI Vaccines Inc
Jounce Therapeutics Inc
Oncosec Medical Inc
Abbvie Inc
BionTech Co Ltd
Greenwich LifeSciences Inc
CRISPR Therapeutics, Inc
Allogene Therapeutics Inc
Xilio Therapeutics Inc
Candel Therapeutics Inc
Concentra Biosciences LLC

Table of Contents

1. Preface

1.1. Contents

1.2. Abbreviations

1.3. Related Reports

2. Executive Summary

3. Immuno-Oncology Overview

3.1. What is IO?

3.2. What is Immuno-oncology According to Regulators?

3.3. Most Important Milestones of Immuno-oncology Development Globally

3.4. Key Twitter Chat

4. Trends

4.1. Industry Trends – Bispecific Antibodies

4.2. Industry Trends – Cancer Vaccines

4.3. Industry Trends – Cell Therapies

4.4. Industry Trends – Checkpoint Modulators

4.5. Industry Trends – Cytokines

4.6. Industry Trends – Oncolytic Viruses

4.7. Regulatory Trends

5. Value Chain

5.1 Immuno-oncology Value Chain

5.2 Bispecific Antibodies

5.3 Cancer Vaccines

5.4 Cell Therapies

5.5 Checkpoint Modulators

5.6 Next-generation Cytokines

5.7 Oncolytic Viruses

5.8 Immuno-oncology in Clinical Trials

6. Marketed Products

6.1. Immuno-Oncology Marketed Products in the 8MM

6.2. Total Market Size for IO Agents

6.3. 10 Highest-Grossing IO Treatments in 2022

6.4. Leading Checkpoint Modulators in the 8MM

6.5. Leading BiTEs in the 8MM

6.6. Leading Cancer Vaccines and Oncolytic Viruses in the 8MM

6.7. Leading Cell Therapies in the 8MM

7. Pipeline Products

7.1. IO Pipeline Products in the 8MM

7.2. Future Outlook of IO Agents, According to High-Prescribing Physicians

7.3. Consensus Forecast Sales for the Top Three Pipeline Candidates

7.4. The Forecast Highest-Grossing Bispecific Antibody Products

7.5. The Forecast Highest-Grossing Vaccine Products

7.6. The Forecast Highest-Grossing Cell Therapy Products

7.7. The Forecast Highest-Grossing Checkpoint Modulator Products

7.8. The Forecast Highest-Grossing Cytokine Products

7.9. The Forecast Highest-Grossing Oncolytic Virus Products

8. Market Analysis

8.1. Market Analysis and Forecast of the Six Classes of IO Agents

8.2. Top 10 Strategic Partnership Deals of the Last Decade by Size in the IO Space

8.3. Latest Strategic Partnership Deals in the IO Space

8.4. Top 10 Mergers and Acquisitions that Include IO Assets: 2018–2023

8.5. Latest Mergers and Acquisitions that Include IO Assets

9. Regulatory and Market Access

9.1. IO in Clinical Trials

9.2. Endpoints in IO Clinical Trials – KOL Perspective

9.3. Challenges in IO Clinical Trials – KOL Perspective

9.4. Regulatory and Market Access – US

9.5. Regulatory and Market Access – EU

9.6. Regulatory and Market Access – Japan

9.7. Regulatory and Market Access – China

9.8. Early Access Schemes

9.9. Barriers to Access According to High Prescribers

10. Opportunities, Challenges, and Unmet Needs

10.1. Bispecific Antibodies

10.2. Cancer Vaccines

10.3. Cell Therapies

10.4. Checkpoint Modulators

10.5. Cytokines

10.6. Oncolytic Viruses

10.7. Clinical Unmet Needs in IO – Gap Analysis

10.8. Commercial Unmet Needs in Immuno-oncology – Gap Analysis

10.9. Unmet Needs – KOL Perspective

10.10 . Unmet Needs According to High Prescribers

10.11 R&D Strategies

10.12 Opportunities for the Industry – Modern Approaches & Collaboration

10.13 Closing Remarks – In Their Words

11. Companies

11.1. Drug Development Scorecard

11.2. Current Major Players – Novartis

11.3. Current Major Players – Merck & Co.

11.4. Current Major Players – Gilead Sciences

11.5. Current Major Players – Roche

11.6. Current Major Players – BMS

11.7. Current Major Players – AstraZeneca

11.8. Current Major Players – Sanofi

11.9. Current Major Players – Amgen

11.10. Current Major Players – Dendreon Pharmaceuticals

11.11. Current Major Players – Legend Biotech

11.12. Current Major Players – Johnson & Johnson

11.13. Current Major Players – Daiichi-Sankyo

11.14. Current Major Players – Kite

11.15. Current Major Players – Regeneron

11.16. Future Players Based on Pipeline Strength – Genmab

11.17. Future Players Based on Pipeline Strength – Iovance Therapeutics

11.18. Future Players Based on Pipeline Strength – Replimune

11.19. Future Players Based on Pipeline Strength – VBI Vaccines

11.20. Future Players Based on Pipeline Strength – Jounce Therapeutics

11.21. Future Players Based on Pipeline Strength – Oncosec

11.22. Future Players Based on Pipeline Strength – Abbvie

11.23. Future Players Based on Pipeline Strength – BioNTech

11.24. Future Players Based on Pipeline Strength – Greenwich LifeSciences

11.25. Future Players Based on Pipeline Strength – CRISPR Therapeutics

11.26. Future Players Based on Pipeline Strength – Allogene Therapeutics

11.27. Future Players Based on Pipeline Strength – Xilio Therapeutics

11.28. Future Players Based on Pipeline Strength – Candel Therapeutics

12. Appendix

12.1. Sources

12.2. Primary Research

12.3. Key Themes Impacting the Pharmaceutical Industry

12.4. Our Thematic Research Methodology

12.5. About the Authors

13. Contact Us

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

We are confident about Immuno-Oncology (IO) – Thematic Intelligence report's unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Immuno-Oncology (IO) – Thematic Intelligence in real time.

  • Access a live Immuno-Oncology (IO) – Thematic Intelligence dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.